Surrozen Inc - Asset Resilience Ratio
Surrozen Inc (SRZN) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Surrozen Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2023)
This chart shows how Surrozen Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Surrozen Inc's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Surrozen Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore SRZN long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Surrozen Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Surrozen Inc Industry Peers by Asset Resilience Ratio
Compare Surrozen Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Surrozen Inc (2020–2023)
The table below shows the annual Asset Resilience Ratio data for Surrozen Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $46.08 Million | -- |
| 2022-12-31 | 57.19% | $51.15 Million | $89.44 Million | +7.06pp |
| 2021-12-31 | 50.13% | $68.76 Million | $137.17 Million | +27.25pp |
| 2020-12-31 | 22.88% | $14.20 Million | $62.06 Million | -- |
About Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, … Read more